EP3256488A4 - Nouveaux antigènes mineurs d'histocompatibilité et leurs utilisations - Google Patents

Nouveaux antigènes mineurs d'histocompatibilité et leurs utilisations Download PDF

Info

Publication number
EP3256488A4
EP3256488A4 EP16748510.1A EP16748510A EP3256488A4 EP 3256488 A4 EP3256488 A4 EP 3256488A4 EP 16748510 A EP16748510 A EP 16748510A EP 3256488 A4 EP3256488 A4 EP 3256488A4
Authority
EP
European Patent Office
Prior art keywords
histocompatibility antigens
minor histocompatibility
novel minor
novel
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16748510.1A
Other languages
German (de)
English (en)
Other versions
EP3256488A1 (fr
Inventor
Claude Perreault
Diana Paola Granados
Jean-Sébastien DELISLE
Pierre Thibault
Sébastien LEMIEUX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
RSEM LP
Original Assignee
Universite de Montreal
RSEM LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal, RSEM LP filed Critical Universite de Montreal
Publication of EP3256488A1 publication Critical patent/EP3256488A1/fr
Publication of EP3256488A4 publication Critical patent/EP3256488A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16748510.1A 2015-02-09 2016-02-09 Nouveaux antigènes mineurs d'histocompatibilité et leurs utilisations Withdrawn EP3256488A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113727P 2015-02-09 2015-02-09
PCT/CA2016/050116 WO2016127249A1 (fr) 2015-02-09 2016-02-09 Nouveaux antigènes mineurs d'histocompatibilité et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3256488A1 EP3256488A1 (fr) 2017-12-20
EP3256488A4 true EP3256488A4 (fr) 2018-10-17

Family

ID=56613958

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16748510.1A Withdrawn EP3256488A4 (fr) 2015-02-09 2016-02-09 Nouveaux antigènes mineurs d'histocompatibilité et leurs utilisations

Country Status (6)

Country Link
US (2) US10414813B2 (fr)
EP (1) EP3256488A4 (fr)
JP (1) JP2018505682A (fr)
AU (1) AU2016218902A1 (fr)
CA (1) CA2974261A1 (fr)
WO (1) WO2016127249A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152633A1 (fr) * 2017-02-22 2018-08-30 Université de Montréal Nouveaux antigènes mineurs d'histocompatibilité et leurs utilisations
GB202403241D0 (en) * 2024-02-16 2024-04-17 Dana Farber Cancer Inst Inc Minor histocompatibility antigen markers associated with graft versus leukemia effect and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108920A1 (en) * 2001-09-07 2003-06-12 Wei Zhang Tumor suppressor-like proteins that bind IGFBP2
WO2007053644A2 (fr) * 2005-11-01 2007-05-10 The Board Of Regents Of The University Of Oklahoma Cartographie comparative des ligands de cellules positives vis-a-vis du mhc de classe i
US20080207497A1 (en) * 2000-12-04 2008-08-28 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2014026277A1 (fr) * 2012-08-15 2014-02-20 Université de Montréal Procédé pour l'identification de nouveaux antigènes d'histocompatibilité mineure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0996636T3 (da) * 1997-07-23 2005-04-25 Univ Leiden HA-1-antigenet
EP1020519A1 (fr) * 1999-01-15 2000-07-19 Introgene B.V. Antigènes d'histocompatibilité mineurs et leur utilisation pour le diagnostic et le traitement des tumeurs
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002213694A1 (en) * 2000-11-02 2002-05-15 Compatigene Inc T-cells specifically recognizing minor histocompatibility antigen(s) and uses thereof for eliminating target cells
WO2010116375A1 (fr) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Peptides isolés pour réguler l'apoptose
CN102636898B (zh) * 2012-03-14 2014-03-12 京东方科技集团股份有限公司 一种柔性显示装置的制备方法
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207497A1 (en) * 2000-12-04 2008-08-28 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20030108920A1 (en) * 2001-09-07 2003-06-12 Wei Zhang Tumor suppressor-like proteins that bind IGFBP2
WO2007053644A2 (fr) * 2005-11-01 2007-05-10 The Board Of Regents Of The University Of Oklahoma Cartographie comparative des ligands de cellules positives vis-a-vis du mhc de classe i
WO2014026277A1 (fr) * 2012-08-15 2014-02-20 Université de Montréal Procédé pour l'identification de nouveaux antigènes d'histocompatibilité mineure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016127249A1 *

Also Published As

Publication number Publication date
US10414813B2 (en) 2019-09-17
EP3256488A1 (fr) 2017-12-20
AU2016218902A1 (en) 2017-08-10
US20180030112A1 (en) 2018-02-01
CA2974261A1 (fr) 2016-08-18
US20190359681A1 (en) 2019-11-28
JP2018505682A (ja) 2018-03-01
WO2016127249A1 (fr) 2016-08-18

Similar Documents

Publication Publication Date Title
EP3215175A4 (fr) Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
EP3229838A4 (fr) Anticorps anti-c10orf54 et leurs utilisations
SMT202500263T1 (it) Anticorpi anti-pro-miostatina/miostatina latente e loro usi
EP3099677A4 (fr) Dérivés de diaminopyrimidine benzènesulfone et leurs utilisations
EP3094325A4 (fr) Hétéroaryles et utilisations de ceux-ci
EP3186277A4 (fr) Anticorps, compositions et leurs utilisations
EP3237450A4 (fr) Anticorps agonistes anti-mertk et leurs utilisations
EP3183262A4 (fr) Nouveaux conjugués de glycane et leur utilisation
EP3215538A4 (fr) Anticorps anti-cd39 et utilisations
EP3188749A4 (fr) Compositions tolérogènes et procédés associés
EP3149037A4 (fr) Glycoanticorps anti-her2 et leurs utilisations
EP3099171A4 (fr) Dérivés de dihydroptéridinone et leurs utilisations
EP3206696A4 (fr) Sharn multiplexés et leurs utilisations
EP3179983A4 (fr) Compositions anti-méthanogéniques et leurs utilisations
EP3218098A4 (fr) Systèmes et procédés de microréacteur
EP3124842A4 (fr) Support de conduit mobile et unité de support
EP3359563B8 (fr) Récepteurs d'antigènes et leurs utilisations
EP3142705A4 (fr) Conjugué polymere-flavonoïde et utilisations associées
CA3265373A1 (fr) Anticorps anti-acth et leur utilisation
EP3094326A4 (fr) Hétéroaryles et utilisations de ceux-ci
EP3191114A4 (fr) Formulations d'occidiofongine et utilisations associées
EP3229842A4 (fr) Polymères lipocationiques et leurs utilisations
EP3177648B8 (fr) Anticorps anti-ténascine-c et utilisations
EP3529273A4 (fr) Anticorps anti-o1 et leurs utilisations
EP3204411A4 (fr) Anticorps anti-tau et ses utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/12 20060101ALI20180607BHEP

Ipc: C07K 7/08 20060101ALI20180607BHEP

Ipc: C12N 5/0784 20100101ALI20180607BHEP

Ipc: C07K 14/74 20060101ALI20180607BHEP

Ipc: C12N 5/10 20060101ALI20180607BHEP

Ipc: C12N 5/078 20100101ALI20180607BHEP

Ipc: A61P 35/02 20060101ALI20180607BHEP

Ipc: A61P 37/04 20060101ALI20180607BHEP

Ipc: C07K 7/06 20060101ALI20180607BHEP

Ipc: A61P 35/00 20060101ALI20180607BHEP

Ipc: A61K 39/00 20060101ALI20180607BHEP

Ipc: C07K 14/705 20060101AFI20180607BHEP

Ipc: C12N 5/0783 20100101ALI20180607BHEP

Ipc: C07K 14/725 20060101ALI20180607BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180914

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/04 20060101ALI20180911BHEP

Ipc: C12N 5/10 20060101ALI20180911BHEP

Ipc: C07K 14/705 20060101AFI20180911BHEP

Ipc: C12N 5/0783 20100101ALI20180911BHEP

Ipc: A61P 35/00 20060101ALI20180911BHEP

Ipc: C12N 5/0784 20100101ALI20180911BHEP

Ipc: A61P 35/02 20060101ALI20180911BHEP

Ipc: C12N 15/12 20060101ALI20180911BHEP

Ipc: C07K 7/08 20060101ALI20180911BHEP

Ipc: C07K 7/06 20060101ALI20180911BHEP

Ipc: C07K 14/74 20060101ALI20180911BHEP

Ipc: C07K 14/725 20060101ALI20180911BHEP

Ipc: C12N 5/078 20100101ALI20180911BHEP

Ipc: A61K 39/00 20060101ALI20180911BHEP

17Q First examination report despatched

Effective date: 20190625

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20200225

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200707